指南与共识糖尿病

支持内分泌学会指南的系统综述:糖尿病及低血糖高风险的管理

A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.
指南 / 共识 · J Clin Endocrinol Metab · 2023-01-01

本系统综述由内分泌学会指南专家组提出10个问题,检索多个数据库,纳入149项研究共43344例患者,采用GRADE方法评估证据确定性,总结持续葡萄糖监测、胰岛素类似物、结构化教育、胰高血糖素制剂等干预对低血糖的影响,为指南制定提供证据基础。

要点

  • 持续葡萄糖监测可减少1型糖尿病严重低血糖发作及低血糖患者比例。
  • 住院患者启用持续葡萄糖监测可减少血糖低于54 mg/dL的低血糖发作。
  • 长效基础胰岛素类似物与较少低血糖相关,速效类似物与严重低血糖减少相关但轻中度低血糖更多。

核心结论

  • 本系统综述总结了针对糖尿病患者低血糖多种干预措施的最佳可用证据,该证据基础将促进内分泌学会制定临床实践指南。

研究设计与样本

  • 系统综述由内分泌学会指南专家组提出10个问题,检索多个数据库,可行时进行Meta分析,采用GRADE方法评估证据确定性。
  • 共纳入149项研究,报告43344例患者。

主要发现

  • 持续葡萄糖监测减少1型糖尿病患者的严重低血糖发作,并减少低血糖(血糖<54 mg/dL)患者比例。
  • 关于1型糖尿病患者使用实时持续葡萄糖监测联合算法驱动胰岛素泵与每日多次注射联合血糖检测的比较,无数据。
  • 门诊使用胰岛素和/或磺脲类药物的2型糖尿病患者中,持续葡萄糖监测减少血糖低于70 mg/dL的时间。
  • 住院低血糖高风险患者中启用持续葡萄糖监测减少血糖低于54 mg/dL的低血糖发作及低于54 mg/dL的时间。
  • 持续葡萄糖监测检测到的血糖低于70 mg/dL和低于54 mg/dL的低血糖患者比例显著高于即时血糖检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Interventions targeting hypoglycemia in people with diabetes are important for improving quality of life and reducing morbidity and mortality. OBJECTIVE: To support development of the Endocrine Society Clinical Practice Guideline for management of individuals with diabetes at high risk for hypoglycemia. METHODS: We searched several databases for studies addressing 10 questions provided by a guideline panel from the Endocrine Society. Meta-analysis was conducted when feasible. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess certainty of evidence. RESULTS: We included 149 studies reporting on 43 344 patients. Continuous glucose monitoring (CGM) reduced episodes of severe hypoglycemia in patients with type 1 diabetes (T1D) and reduced the proportion of patients with hypoglycemia (blood glucose [BG] levels <54 mg/dL). There were no data on use of real-time CGM with algorithm-driven insulin pumps vs multiple daily injections with BG testing in people with T1D. CGM in outpatients with type 2 diabetes taking insulin and/or sulfonylureas reduced time spent with BG levels under 70 mg/dL. Initiation of CGM in hospitalized patients at high risk for hypoglycemia reduced episodes of hypoglycemia with BG levels lower than 54 mg/dL and time spent under 54 mg/dL. The proportion of patients with hypoglycemia with BG levels lower than 70 mg/dL and lower than 54 mg/dL detected by CGM was significantly higher than point-of-care BG testing. We found no data evaluating continuation of personal CGM in the hospital. Use of an inpatient computerized glycemic management program utilizing electronic health record data was associated with fewer patients with and episodes of hypoglycemia with BG levels lower than 70 mg/dL and fewer patients with severe hypoglycemia compared with standard care. Long-acting basal insulin analogs were associated with less hypoglycemia. Rapid-acting insulin analogs were associated with reduced severe hypoglycemia, though there were more patients with mild to moderate hypoglycemia. Structured diabetes education programs reduced episodes of severe hypoglycemia and time below 54 mg/dL in outpatients taking insulin. Glucagon formulations not requiring reconstitution were associated with longer times to recovery from hypoglycemia, although the proportion of patients who recovered completely from hypoglycemia was not different between the 2 groups. CONCLUSION: This systematic review summarized the best available evidence about several interventions addressing hypoglycemia in people with diabetes. This evidence base will facilitate development of clinical practice guidelines by the Endocrine Society.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Torres Roldan VD, Urtecho M, Nayfeh T, et al. A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia. J Clin Endocrinol Metab. 2023. PMID: 36477885. doi:10.1210/clinem/dgac601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。